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Background: Adiponectin may regulate ovarian steroidogenesis, folliculogenesis and ovulation. The alterations in
the distribution of adiponectin multimers in follicular fluid (FF) and the relationship between adiponectin multimers
and folliculogenesis in women with polycystic ovary syndrome (PCOS) remain unclear. In this study, we aimed to
investigate the association between the levels of total and high molecular weight (HMW) adiponectin in serum and
FF and folliculogenesis in women undergoing in vitro fertilisation (IVF).
Methods: This prospective study included ten Chinese women with PCOS and ten controls undergoing IVF. The
levels of the total and HMW adiponectin in serum and FF were determined by ELISA. Insulin resistance (IR) was
estimated using the homeostasis model assessment insulin resistance index (HOMA-IR).
Results: After controlling for the body mass index (BMI), the levels of the total, and the HMW adiponectin in the
serum and FF were significantly lower in the women with PCOS compared with the normovulatory women
undergoing IVF (P < 0.05). The levels of the HMW adiponectin were significantly lower in the FF than in the serum
(P < 0.01). No significant differences were found in the total adiponectin levels in the serum and in the FF (P > 0.05).
Decreased HMW adiponectin in the FF was associated with an increased number of follicles and decreased
follicular diameters in the normovulatory and PCOS women, and this association was independent of the overall
adiposity. A strong positive linear correlation was observed between the number of the follicles and the IR
estimated by HOMA-IR (r = 0.784, P < 0.0001). We found that the larger follicular diameters had a negative
relationship with the IR estimated by HOMA-IR (r = −0.445, P < 0.05). A strong negative linear correlation was
observed between HOMA-IR and the HMW adiponectin levels (r = −0.726, P < 0.001) and the total adiponectin levels
(r = −0.759, P < 0.001) in the FF.
Conclusions: The levels of the total adiponectin and the HMW adiponectin in the FF and serum were decreased in
the Chinese women with PCOS compared with the normovulatory women undergoing IVF, and the differences
persisted after controlling for the BMI. Ovarian HMW adiponectin is negatively correlated to folliculogenesis.
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Polycystic ovary syndrome (PCOS) is the most common
cause of menstrual dysfunction, infertility, and hyperandro-
genism, and it affects between 6 and 10% of reproductive-
age women [1]. Insulin resistance (IR) has been considered
to be the most important aetiological aspect of the repro-
ductive and metabolic abnormalities in PCOS [2,3]. The
pathophysiology of the ovulatory disorder remains unclear.
Our previous study [4] and other [5,6] evidence of hypoa-
diponectinaemia are strongly associated with the occur-
rence of PCOS, suggesting that deficiency in adiponectin
may play a role in this ovarian disorder.
Adiponectin, a glycoprotein hormone, is mainly pro-
duced by adipocytes [7], and it circulates in different
multimer complexes specifically classified as high mo-
lecular weight (HMW) multimers, medium molecular
weight hexamers (MMW), and low molecular weight
(LMW) trimers [8]. Recent clinical studies have revealed
that the HMW complex is the most biologically potent
form, and it plays a key role in the regulation of IR
[9,10]. In vitro and in vivo studies have shown that adipo-
nectin has beneficial effects on the reproductive processes
and an important relationship with the gonadotropins and
other hormones [11-13]. In animal models, adiponectin
appears to influence ovarian steroidogenesis, folliculogen-
esis, and ovulation. Tabandeh et al. [14,15] reported that
changes in the adiponectin system gene expression in bo-
vine ovarian cells during their morphological and physio-
logical development may be under the influence of
hormonal or biological factors associated with follicu-
lar development. They found a novel association of
adiponectin and its receptor genes with follicular dom-
inance and oocyte competence and suggested the puta-
tive role of the adiponectin system as a novel regulator
of folliculogenesis. In support of a role for adiponectin
in human folliculogenesis and ovulation, circulating
adiponectin positively correlates with the number of
oocytes retrieved in women treated with follicle-stimulating
hormone (FSH) to induce superovulation for in vitro fertil-
isation (IVF) [16]. Taken together, these findings suggest
that the adiponectin system may be associated with the
changes in folliculogenesis events during the final matur-
ation of the follicles after selection.
The role of serum and FF adiponectin and its multi-
mers levels in PCOS women under controlled ovarian
hyperstimulation and their possible predictive value for
the IVF outcome remain unclear. We conducted this
study to investigate the correlation of the total adipo-
nectin and the HMW adiponectin levels in the serum
and follicular fluid (FF) with a number of follicles and
larger follicular diameters in Chinese women with
PCOS compared with the age and body mass index
(BMI)-matched normovulatory women who were under-
going IVF.Methods
Subjects
This prospective study included ten patients with PCOS
and ten women with normal ovulatory function under-
going IVF for treatment of tubal and/or male infertility.
The women were between 20 and 40 years old. The pa-
tients with elevated FSH levels (≥12 mIU/mL) and women
>42 years of age were excluded. The study required no
modification of our routine IVF protocol.
The PCOS diagnosis was based on the National Insti-
tutes of Health 1990 criteria, which include the follow-
ing: i) clinical evidence of hyperandrogenism and/or
hyperandrogenaemia, ii) oligo-ovulation, and iii) the
exclusion of related disorders including nonclassical
21-hydroxylase-deficient adrenal hyperplasia, hyperprolac-
tinaemia, thyroid dysfunction, Cushing’s syndrome, or
androgen-producing tumours [17]. The control women
was referred to the Shanghai Renji hospital Reproduct-
ive Health and Fertility Centre for IVF because of tubal
and/or male infertility. The exclusion criteria were a
history of menstrual disturbances (i.e., cycle length <25 d
or >35 d), hirsutism, an abnormal serum level of prolactin
or androgens (i.e., serum testosterone above 0.6 ng/ml),
and PCO at ultrasonography. All the study evaluations
and procedures were conducted in accordance with the
guidelines of the Helsinki Declaration on human experi-
mentation. The study was approved by the ethics commit-
tee of the Shanghai Renji Hospital, and all the subjects
provided written informed consent.
Ovarian stimulation
Pituitary desensitisation was started with GnRH agonist
triptorelin at 0.1 mg/day (Decapeptyl; Ferring, Sweden)
during the luteal phase before the IVF treatment or after
15 days of oral contraceptives for the patients with dyso-
vulation. The follicle growth was stimulated after 12 d of
desensitisation by injecting recombinant FSH (rFSH;
Puregon; Organon Laboratories, Saint-Denis, France) at
150–450 IU/d. The follicle growth was monitored by the
serum estradiol levels and transvaginal ultrasound. A
5000 IU dose of human chorionic gonadotropin (Profasi,
Serono, Switzerland) was administered when the leading
follicle reached 18–20 mm in diameter with at least
three follicles greater than 16 mm detected by ultrason-
ography. The oocyte retrieval was performed 36 h later
under transvaginal ultrasound guidance.
Collection of the follicular fluids
The follicle size was determined immediately before re-
trieval under ultrasound, and the FF from the larger fol-
licles (17–22 mm) was collected in tubes. We calculated
the number of follicles (>12 mm) for each patient. The
size of the larger follicles was chosen to be similar to that
of a previous study of Fanchin et al. [18]. Nonbloody
Tao et al. Reproductive Biology and Endocrinology 2013, 11:99 Page 3 of 8
http://www.rbej.com/content/11/1/99pooled FF was used and was centrifuged (800 g at 10 min)
and an aliquot of the supernatant was stored at - 80°C
until assayed.
Anthropometric measurements
The height and weight of each subject wearing light
clothing was measured to the nearest 0.1 cm and 0.1 kg,
respectively, using a digital scale and stadiometer. On
each patient’s baseline evaluation day after pituitary sup-
pression with GnRH agonist triptorelin and prior to the
start of gonadotropin stimulation, the BMI was calcu-
lated as the body weight (kg) divided by the height (m)
squared.
Laboratory assays
All the laboratory evaluations were performed in the
fasting state between 7:00 am and 8:00 am on the day of
the oocyte retrieval. The fasting glucose and insulin sam-
ples were stored at 4°C and analysed on the day of the
analysis. All the serum samples for the total adiponectin
and the adiponectin multimeric forms were stored at 80°C
until assayed. The plasma glucose was determined using
the glucose oxidase methodology. All the measurements
were performed with Roche reagents (D 2400 and E 170
Modular Analytics modules with Roche/Hitachi analysers;
Roche Diagnostics). The insulin levels were measured by
Radioimmunoassay (RIA). The intra-assay CV of the insu-
lin and of the steroid hormone assays were 5.5 and <10%,
respectively. To estimate the IR, the homeostasis model
assessment IR index (HOMA-IR) was calculated ac-
cording to the following formula: fasting serum insulin
(mUI/ml) × fasting plasma glucose (mmol/l)/22.5 [19].
Competitive electrochemiluminescence immunoassays on
the Elecsys autoanalyser 2010 (Roche Diagnostics) were
used to quantify the serum estradiol levels. The follicular
fluid levels of the total and HMW adiponectin were mea-
sured for each patient on the day of the oocyte retrieval. All
the vaginal oocyte retrievals occurred between 7:00 am and
10:00 am.
The concentration of the total adiponectin and the
HMW adiponectin in the serum and FF were assayed
directly in the identical plate using the double-monoclonal
sandwich ELISA method (Daiichi Pure Chemicals, Tokyo,
Japan, distributed by ALPCO diagnostics). To detect the
HMW adiponectin, the serum samples were pretreated
with a protease that selectively digested the MMW and
LMW adiponectin species. This specific assay for the
adiponectin multimers demonstrates a sensitivity of
0.04 ng/ml; an inter-assay CV < 15%; and an intra-assay
CV of 5.3% and 3.3% for the total and the HMW-
adiponectin, respectively [20]. The assays were read on a
plate reader using the standard curves that were created
using a blank medium as the diluent. All the samples and
standards were assayed in triplicate.Statistical analysis
All the statistical analyses were performed using SPSS
version 17.0 (Statistical Package for the Social Sciences,
USA). The data were considered statistically significant
at P < 0.05. The distributions of the continuous variables
were tested for normality with the Kolmogorov-Smirnov
test. The portions of the results not normally distributed
based on the normal quartile plot were log-transformed
for all the statistical analyses and reported back trans-
formed in their original units. All the results were re-
ported as the means with SD or 95% confidence intervals
(CIs) or as geometric means for the log-transformed vari-
ables relative or not to the basal state, which are represen-
tative of at least three independent experiments. For the
normally distributed data, a t-test was used to compare
the mean values between the two groups. For the data that
were not normally distributed, a Mann–Whitney rank
sum test was used to compare the mean values between
the two groups. The relationships between the levels of
the total and the HMW adiponectin in the FF and a num-
ber of follicles and larger follicular diameters and IR were
evaluated by Spearman’s correlation tests.
Results
The clinical, hormonal and metabolic features of the
subjects
The clinical characteristics and biochemical variables in
the normovulatory women and the women with PCOS
are summarised in Table 1. No differences between the
two groups were found for the age, mean BMI, estradiol
levels at HCG day,started dose of rFSH and the total
dose of rFSH received by each patient (all P > 0.05). The
fasting glucose and insulin level, HOMA-IR and number
of follicles were significantly higher in the PCOS group
(all P < 0.05). The larger follicular diameters were signifi-
cantly lower in the PCOS group compared with the
BMI-matched normovulatory women (P < 0.001).
Low levels of total and HMW adiponectin in the serum
and FF in women with PCOS undergoing controlled
ovarian hyperstimulation
As shown in Figure 1, the mean total adiponectin values
were significantly lower in the serum (6.74 ± 0.40 vs.
9.88 ± 0.93 ug/ml, P = 0.011) and FF (7.35 ± 0.43 vs. 11.93 ±
0.76 ug/ml, P = 0.000)in the women with PCOS undergoing
controlled ovarian hyperstimulation. The mean HMW
adiponectin values were significantly lower in the serum
(2.95 ± 0.21 vs. 4.59 ± 0.39 ug/ml, P = 0.000) and FF (1.57 ±
0.13 vs. 2.68 ± 0.19 ug/ml, P = 0.002) in the women with
PCOS undergoing controlled ovarian hyperstimulation.
Compared with the serum HMW adiponectin levels, the
HMW adiponectin levels in the FF were significantly
lower in the PCOS group and control group (P = 0.007
and P = 0.002, respectively). There were no significant
Table 1 The clinical and biochemical variables in the women with and without PCOS undergoing IVF
Variable PCOS Control P
Patients 10 10 ns
Age (years) 34.1 +/− 4.4 33.1 +/− 5.4 0.491
BMI (kg/m2) 27.2 +/− 2.5 26.5 +/− 2.90 0.502
Started dose of rFSH(IU) 155 (127.9-182.1) 190 (171.7-208.3) 0.052
rFSH total (IU) 1625 (1297–2260) 2250 (1188–2810) 0.152
Estradiol (pg/ml) at HCG day 5239.3 (4256.3-6222.3) 4411.7 (3319.7-5503.7) 0.199
FBG (mmol/L) 5.4 +/− 0.5 4.8 +/− 0.4 0.008
Fasting Insulin (mIU/L) 26.3 +/− 4.5 15.2 +/− 2.9 0.000
HOMA-IR 6.3 +/− 1.1 3.2 +/− 0.5 0.000
Number of follicles 25 +/− 5 10 +/− 3 0.000
Larger follicular diameters (mm) 19.4 +/− 0.8 21.2 +/− 1.3 0.002
The values are given as the means ± SD or the means (95% CI). The P value for the t-test or Mann–Whitney U tests for the difference between the two groups.
The BMI, body mass index; FSH, follicle-stimulating hormone; FBG, fasting blood glucose; HOMA-IR, homeostasis model assessment - insulin resistance index. To
convert the glucose to mg/dL, divide by 0.05551.
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serum and the FF between the women with and with-
out PCOS undergoing controlled ovarian hyperstimu-
lation (P = 0.105 and P = 0.316, respectively).
Correlation between HOMA-IR and the number of follicles
and the larger follicular diameters
As shown in Table 2, considering all the women with
and without PCOS undergoing controlled ovarian hyper-
stimulation, a strong positive linear correlation was ob-
served between the number of follicles and the insulin
resistance estimated by HOMA-IR (r = 0.784, P < 0.0001),
and the larger follicular diameters had a negative relation-
ship with the insulin resistance estimated by HOMA-IR
(r = −0.445, P < 0.05). A strong negative linear correlationFigure 1 The levels of the total and HMW adiponectin in the plasm
A demonstrates the total adiponectin and B demonstrates the HMW ad
significantly decreased in the plasma (White Box) and the FF (Black box)
Compared with the plasma HMW adiponectin levels (White Box), the HM
the PCOS group and the control group (P = 0.007 and P = 0.002, respect
and Mann–Whitney U tests for the difference between the two groups.was observed between the HOMA-IR and HMW adi-
ponectin levels (r = −0.726, P < 0.001) and the total
adiponectin levels (r = −0.759, P < 0.001) in the FF.
Correlation between the levels of the total and HMW
adiponectin in the FF and the number of follicles and
larger follicular diameters
As shown in Figure 2, considering all the women with
and without PCOS undergoing controlled ovarian hyper-
stimulation, a positive linear correlation was observed
between the larger follicular diameters and the HMW
adiponectin levels in the FF (r = 0.474, P < 0.05). We did
not find that the total adiponectin levels in the FF have
strong linear relationships with larger follicular diame-
ters (r = 0.431, P = 0.058). We found that the number ofa and FF in the IVF women with PCOS and the controls.
iponectin levels; overall, among the women with PCOS, both were
(P < 0.001 and P = 0.002, respectively) in comparison to controls.
W adiponectin levels in FF (Black box) were significantly lower in
ively). The data are the means ± SEM. The P-value for the Wilcoxon
Table 2 The correlation between HOMA-IR and total and
HMW adiponectin and the number of follicles and larger




Number of follicles −0.784 <0.001
Larger follicular diameters −0.445 0.049
Total adiponectin in FF −0.759 <0.0001
HMW adiponectin in FF −0.726 <0.0001
Total adiponectin in serum −0.586 0.007
HMW adiponectin in serum −0.763 <0.0001
P-value for Spearman’s correlation tests.
HMW - high molecular weight, FF-follicular fluid, HOMA-IR - homeostasis
model assessment - insulin resistance index.
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HMW adiponectin levels (r = −0.629, P = 0.003) and the
total adiponectin levels (r = −0.679, P = 0.001) in the FF.
Correlation between the levels of the total and the HMW
adiponectin in the serum and the number of follicles and
larger follicular diameters
As shown in Figure 3, considering all the women with
and without PCOS undergoing controlled ovarian hyper-
stimulation, a strong negative linear correlation was ob-
served between the number of follicles and the HMW
adiponectin levels (r = −0.574, P = 0.008) and the total
adiponectin levels (r = −0.522, P = 0.018) in the serum.
We did not find that the total adiponectin and the
HMW adiponectin levels in the serum have strong linear
relationships with larger follicular diameters (P > 0.05 for
both).
Discussion
The major finding of this study is the demonstration
that lower HMW adiponectin and total adiponectin
levels in FF and serum was an important feature in go-
nadotropin stimulated PCOS patients. Decreased HMW
adiponectin levels in the FF was associated with de-
creased larger follicular diameters in normovulatory and
PCOS women under IVF, and this association is inde-
pendent of overall adiposity. The HMW adiponectin
provided a stronger relationship with larger follicular di-
ameters than the total adiponectin among all the women
under IVF. Our data suggested that IR, estimated by
HOMA-IR, at least partially predicts a reflection of ovar-
ian stimulation in IVF patients.
Findings from previous animal studies show that adi-
ponectin provokes the expression of genes associated
with peri-ovulatory remodelling of the ovarian follicle
and may be involved in the regulation of follicle matur-
ation and ovulation [12,21,22]. Multiple endocrine and
intraovarian paracrine interactions may influence theintrafollicular microenvironment for appropriate oocyte
development. The concentrations of adipokines in FF
correlate with folliculogenesis and oocytes more than
with implantation and embryonic development. Recent
studies showed that endocrine/paracrine abnormalities
and metabolic dysfunction impaired folliculogenesis in
PCOS patients and determined the outcome of assisted
reproductive technologies (ART) [23]. The findings of
our previous study suggested that it is possible that al-
terations in the adiponectin multimers may contribute
to the phenotypic presentation of PCOS via metabolic
pathways independent of IR [4]. We suggested that the
potential contributions of the alterations in the adipo-
nectin multimers such as HMW adiponectin in FF are
implicated in the pathogenesis of ovulatory dysfunction
in PCOS women.
Our study directly compared the two compartments
(serum and FF) in the same patients at the same time. In
this study, we demonstrated for the first time that the
levels of HMW adiponectin in FF were significantly
lower in the women with PCOS undergoing IVF com-
pared with the BMI-matched normovulatory women.
The HMW adiponectin was approximately two times
lower in the FF than in the serum (Figure 1). The follicu-
lar fluid HMW adiponectin levels, but not the total adi-
ponectin levels, had a significant positive correlation
with larger follicular diameters. These findings suggest
that the change in an intrafollicular HMW adiponectin
environment plays a potential role in folliculogenesis in
women undergoing IVF. We did not find that the total
adiponectin levels in FF have strong linear relationships
with larger follicular diameters. This finding seems to
suggest that intrafollicular HMW adiponectin may be
more important than total adiponectin in predicting lar-
ger follicular diameters in PCOS and non-PCOS women
undergoing IVF. Based on our data, causality cannot be
established. There should be further investigation of the
potential mechanisms of the intrafollicular HMW adipo-
nectin levels that predicted a reflection of ovarian stimu-
lation in IVF patients.
We hypothesize that the detected amount of HMW adi-
ponectin, with its even lower FF-to-serum concentration
ratio of 0.5 in the FF, may not be the result of passive diffu-
sion but could be the combination effect of endocrine fac-
tors, including those of insulin and the gonadotropins. This
finding is further strengthened by the result of this study
[24], which was the presence of a high concentration of in-
sulin in the FF in the non-pregnant cycles of patients with
PCOS. It is regretted that we did not detect the concentra-
tion of insulin in the FF in the present study. The levels of
HOMA-IR demonstrated a strong inverse linear relation-
ship with the HMW adiponectin levels in the FF. The pre-
cise mechanisms are unclear, and the lower intrafollicular
HMW adiponectin levels should be further investigated.
Figure 2 Correlation between the levels of the HMW adiponectin and the total adiponectin in the FF and the number of follicles and
larger follicular diameters among the women with and without PCOS undergoing IVF. The number of follicles had a strong negative
relationship with the HMW adiponectin levels (r = −0.629, P = 0.003) (A) and the total adiponectin levels (r = −0.679, P = 0.001) (C) in the FF.
B demonstrates that a positive linear correlation was observed between larger follicular diameters and HMW adiponectin levels in the FF (r = 0.474,
P < 0.05). We did not find that the total adiponectin levels in the FF have strong linear relationships with larger follicular diameters (r = 0.431,
P = 0.058) (D). The P-value for Spearman’s correlation tests.
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and serum total adiponectin levels with the IVF out-
comes in women undergoing controlled ovarian hyper-
stimulation have yielded conflicting results [24-27].
Findings of Bersinger NA [25] showed higher levels of
total adiponectin in serum on the day of oocyte pick-up
(OPU) but not in the FF leading to pregnancy, compared
with unsuccessful cycles. A recent study [26] showed
that no correlations were observed for total adiponectin
or its isoforms in the serum and the FF with estradiol,
progesterone, anti-Mullerian hormone, inhibin B, or the
total FSH dose administered during the ovarian stimulation
phase. They observed a trend towards higher HMW adipo-
nectin serum levels in successful ICSI cycles compared to
implantation failure cycles. Takikawa et al. [24] reportedthat there was no significant difference in the concentra-
tion of adiponectin in the FF between pregnant and
non-pregnant cycles; they did find high concentrations
of insulin in the FF in non-pregnant cycles of patients
with PCOS that suggested the possible involvement of
intrafollicular insulin in folliculogenesis. This finding is
in contrast to other studies, which found that the lep-
tin to adiponectin ratio (L: A ratio) in the follicular
fluid of the preovulatory follicle is related to successful
in vitro embryo development and that this action may
be independent of FF insulin [27].
Some findings of the present study contrast with the
results of two of these reports [24,26]. Several explana-
tions for the alleged disparity in these findings can be
hypothesised, including differences in the study subject
Figure 3 The correlation between the levels of HMW adiponectin and total adiponectin in the serum and the number of follicles
among the women with and without PCOS undergoing IVF. A strong negative linear correlation was observed between the number of
follicles and (A) the HMW adiponectin levels (r = −0.574, P = 0.008) and (B) the total adiponectin levels (r = −0.522, P = 0.018) in the serum. The
P-value for Spearman’s correlation test.
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criteria) and different ART and clinical characteristics
(i.e., a higher prevalence of obesity in the present study).
The indexes for the ART outcome and the methodology
used to quantify the adiponectin multimers differed
among the studies.
Several limitations of our study should be considered,
and the primary weakness was the relatively small sample
size. We based the diagnosis of PCOS on the 1990 NIHcriteria, and thus the study represents a less heterogeneous
group of women. The strengths of our study included its
prospective design. All the samples were batched, frozen,
and run together in triplicate to minimise error.
The current data demonstrate that low levels of total
adiponectin and HMW adiponectin in the serum and FF
of PCOS women undergoing IVF and intrafollicular
HMW adiponectin had a significant positive correlation
with larger follicular diameters. Our results support the
Tao et al. Reproductive Biology and Endocrinology 2013, 11:99 Page 8 of 8
http://www.rbej.com/content/11/1/99possible involvement of intrafollicular HMW adiponec-
tin in folliculogenesis. Further investigation is warranted
to determine the mechanisms of the potential contribu-
tions of alterations in HMW adiponectin on ovulatory
dysfunction in PCOS women.
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